TG Therapeutics (TGTX) has disclosed a new risk, in the Debt & Financing category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TG Therapeutics faces heightened business risks with government contracts, which are vulnerable to uncertain funding and stringent compliance demands. Fluctuations in government budgets may lead to reduced or withdrawn funding, impacting the company’s financial stability. Moreover, the possibility of non-renewal or abrupt termination of contracts adds to the operational uncertainty. Compliance with comprehensive procurement laws further burdens TG Therapeutics, potentially affecting its reputation, operational efficiency, and financial outcomes.
Overall, Wall Street has a Moderate Buy consensus rating on TGTX stock based on 4 Buys, 1 Sell and 1 Hold.
To learn more about TG Therapeutics’ risk factors, click here.